NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...
The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.
NEW YORK – Readers interested in precision oncology in 2025 were closely following the evolving regulation and guidelines spurring adoption of DPYD testing. Three out of the top 10 most-read stories ...
Stories about federal funding cuts, lab test regulation, and increasing adoption of DPYD testing were the most popular among readers.
The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.
NEW YORK – Senhwa Biosciences this week said that its investigational agent pidnarulex will be studied in combination with AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in ...
NEW YORK – GenSight Biologics said Monday that the French National Agency for the Safety of Medicines and Health Products (ANSM) has granted compassionate use authorization for its GS010/Lumevoq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback